Cogent Biosciences Q4/FY2024 net loss $67.9M/$255.9M; SUMMIT results due July 2025

Cogent Biosciences, Inc.

2024-FY EPS reported -$1.94

Net loss Q4 $67.9M, FY $255.9M (vs $54.4M and $192.4M); R&D spend $62M/$232.7M.
Cash, equivalents and marketable securities $287.1M at 12/31/24 plus $25M from ATM; runway into late 2026.
Top-line SUMMIT (NonAdvSM) results expected July 2025; APEX (AdvSM) enrollment complete, data 2H 2025.
NDA submission for bezuclastinib planned by end-2025; PEAK (GIST) top-line by end-2025.
Preclinical IND for ErbB2 inhibitor CGT4255 and PI3Kα inhibitor CGT6297 planned in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.